Table 1B. Baselinea disease characteristics of the long-term extension study: golimumab induction responders who received golimumab in the maintenance trial and entered the long-term extension.
| n | Mean±s.d. | Median (IQR) | |
|---|---|---|---|
| Mayo scoreb (0–12) | 201 | 2.3±2.05 | 2.0 (1.0; 3.0) |
| Partial Mayo scoreb (0–9) | 203 | 1.5±1.46 | 1.0 (0.0; 2.0) |
| IBDQc | 201 | 181.9±32.06 | 191.0 (162.0; 209.0) |
| C-reactive protein (mg/l) | 202 | 3.6±6.24 | 1.6 (0.5; 3.6) |
IBDQ, inflammatory bowel disease questionnaire; IQR, interquartile range.
a
Baseline disease characteristics were collected at week 54 of the maintenance trial (i.e., week 0 of long-term extension).
b
Mayo scores range from 0 to 12, with higher scores indicating more severe disease. The partial Mayo scores (excluding the endoscopy subscore) range from 0 to 9, with higher scores indicating more severe disease.
c
IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life.